Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
-
BUSINESS Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
November 29, 2018
-
REGULATORY AMED Study Group Drafting Japan’s 1st Guidelines for Development of Recombinant Virus Vaccines
November 29, 2018
-
TRENDS Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
November 28, 2018
-
BUSINESS Keytruda Continues to Close in on Opdivo in July-September Global Sales
November 27, 2018
-
REGULATORY MHLW Proposes Introduction of Administrative Fines for Improperly Earned Revenues
November 27, 2018
-
BUSINESS Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
November 26, 2018
-
REGULATORY MHLW Eyes Drastic Change to Cost Effective Analysis Flow, Enhanced Discussions Upfront
November 22, 2018
-
REGULATORY MHLW Proposes Quarterly Product Selections, Price Tweaks for CEA Scheme: Chuikyo
November 22, 2018
-
BUSINESS Pfizer’s ALK Inhibitor Lorbrena, Shire’s HAE Drug Now Available in Japan
November 21, 2018
-
BUSINESS Mitsubishi Tanabe Cuts FY2020 Targets in 5-Year Biz Plan on Flagging Royalty, Development Delay
November 21, 2018
-
BUSINESS 3 Japan Generic Majors Log 6% Growth in Combined April-September Sales despite Price Revision
November 20, 2018
-
BUSINESS 4 Major Wholesalers See 46.1% Increase in 1st Half Operating Profit due to Reductions in Yakkasa and SGA Costs
November 19, 2018
-
BUSINESS AstraZeneca Japan Set to Roll Out 4 New Treatments Every Year through 2021: Chief
November 16, 2018
-
REGULATORY Keytruda’s MSI-H Cancer Use Up for MHLW Panel Review Nov. 29; Wider Hemlibra Indication, 1st Line Tecentriq Also on Agenda
November 16, 2018
-
BUSINESS Hib Vaccine Wind-Up, Development Flop Trigger GSK, Daiichi Sankyo to Shutter JV
November 15, 2018
-
REGULATORY Chuikyo Agrees on October 2019 Drug Price Revision for Tax Hike, but Final Call Is Up to Govt
November 15, 2018
-
REGULATORY Maviret Faces 25% Price Slash in Quarterly Review
November 14, 2018
-
BUSINESS GSK, Daiichi Sankyo Dissolve Vaccine JV
November 14, 2018
-
REGULATORY Novartis’ SMA Gene Therapy Filed in Japan on Nov. 1 after US, EU; What Will Happen to Sakigake Status?
November 13, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…